CATALYST is an exciting new program launched by Allied-Bristol Life Sciences (ABLS) to: 1) identify therapeutic opportunities with strong translational potential and that are aligned with ABLS’s strategic areas of interest; and 2) license and develop lead compounds, investing ~$12M to $16M per program to undertake pre-clinical development and position the opportunity for further clinical development and commercialization by BMS. For more information on eligibility, selection criteria, and process, please click here.